Company intelligence / Profile preview

Concord Medical

Beijing, China

Ownership: Private
Employees: ~595
Development stage: Other

Overview

Concord Medical operates comprehensive cancer centers and a large network of radiotherapy and diagnostic imaging facilities in China, providing advanced cancer diagnosis and treatment. Its Guangzhou center began clinical trial operations for proton therapy in November 2022 and is now approved for treatment as of December 2024. The company is a leading oncology service provider in China, with a significant commercial presence and growing clinical technology capabilities.

Therapeutic areas: Oncology
Modalities: Proton therapyRadiotherapyImagingDevice
Industry: Non-Academic Healthcare

Partnerships

Collaboration with public and private hospitals across China to co-develop oncology centers and provide technology and service management

Beyond the preview

Go deeper on Concord Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concord Medical.

Explore the full profile